6533b85cfe1ef96bd12bc9d0
RESEARCH PRODUCT
Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency
Philipp S. WildVincent Ten CateLisa EggebrechtChristoph BickelThomas MünzelEduard UhrichMichael LauterbachMarina Panova-noevaChristine Espinola-kleinSebastian GöbelMarkus NaglerJürgen H. Prochaskasubject
medicine.medical_specialtymedicine.medical_treatmentlcsh:MedicineRenal function030204 cardiovascular system & hematologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineRenal replacement therapyAdverse effectcoagulation serviceOral anticoagulationoral anticoagulationCreatininevitamin k-antagonistsbusiness.industrylcsh:RHazard ratioGeneral Medicineadverse eventschemistrybusinesschronic kidney diseaseCohort studydescription
Oral anticoagulation (OAC) is effective at preventing and treating thromboses and thromboembolism in patients with normal renal function. We aimed to research the impact of severe renal failure (RF) on patient outcome and to determine the potential benefit of caring for these patients in a specialized coagulation service (CS). A total of 1516 usual medical care patients and 756 CS-managed patients of the thrombEVAL multicenter (21 centers), prospective, cohort study (NCT01809015) were analyzed in a 3-year follow-up. Patients with RF (serum creatinine >
year | journal | country | edition | language |
---|---|---|---|---|
2020-02-01 | Journal of Clinical Medicine |